Join us for an insightful session focused on the transition from pediatric to adult care for adolescent and young adult patients with rheumatic diseases. The program, featuring an adult and pediatric rheumatologist, will highlight the current state of transition in rheumatology, as well as the challenges encountered by patients, caregivers, and providers. The role of JAK inhibitors approved for both appropriate pediatric and adult patients will also be explored. Our expert speakers will share their own clinical experiences and solutions for enhancing the transition of care to further improve the patient experience and outcomes. Developed and offered by Pfizer, Inc. Not an official program of the ACR.
Non-CME